Jiangsu Hengrui Pharmaceuticals (600276.SH) has obtained the notification letter of approval for clinical trials of Rivaroxaban tablets.
Hengrui Medicine (600276.SH) announced that the company has recently received approval and issued by the National Medical Products Administration...
Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that they have recently received the approval from the National Medical Products Administration to conduct clinical trials for the drug Rilvarin tablets.
Rilvarin tablets are a second-generation AR inhibitor, with stronger AR inhibitory effects compared to first-generation AR inhibitors, and no excitatory effects. The company's Rilvarin tablets were approved for market in 2022 for the treatment of patients with metastatic hormone-sensitive prostate cancer (mHSPC) with a high tumor burden.
Related Articles
Jiangsu Changshu Rural Commercial Bank (601128.SH) has received an increase in holdings of 0.17% by Changshu Investment Holding Group.
Xi'an Actionpower Electric(688719.SH) shareholders plan to collectively reduce their holdings by no more than 3%.
CSI Properties (00497): Southwater Hong Kong Limited has successfully completed the refinancing of bank financing.
Jiangsu Changshu Rural Commercial Bank (601128.SH) has received an increase in holdings of 0.17% by Changshu Investment Holding Group.
Xi'an Actionpower Electric(688719.SH) shareholders plan to collectively reduce their holdings by no more than 3%.
CSI Properties (00497): Southwater Hong Kong Limited has successfully completed the refinancing of bank financing.
RECOMMEND
Younger consumers are dining out less at Chipotle and Cava while still buying Coach handbags
10/11/2025
Target’s deteriorating in-store experience risks recovery — retailer bets on a refined fulfillment model to fix it
10/11/2025
China suspends approval ban on exports of certain metals used in chip and electronics manufacturing to the U.S.
10/11/2025
